These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 106559)

  • 41. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
    Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
    Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma.
    Giacomini P; Veglia F; Cordiali Fei P; Rehle T; Natali PG; Ferrone S
    Cancer Res; 1984 Mar; 44(3):1281-7. PubMed ID: 6692408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Study on cellular immunity and immunotherapy of malignant melanoma (author's transl)].
    Ishihara K
    Nihon Hifuka Gakkai Zasshi; 1975 Oct; 85(12):696-8. PubMed ID: 1238716
    [No Abstract]   [Full Text] [Related]  

  • 44. Immunobiology of human cutaneous melanoma.
    Cochran AJ; Wen DR; Stene M; Fairhurst MV; Hoon DS
    Prog Clin Biol Res; 1988; 256():597-618. PubMed ID: 3368501
    [No Abstract]   [Full Text] [Related]  

  • 45. Immunology and cutaneous malignant melanoma.
    Sober AJ
    Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical application of monoclonal antibodies to human malignant melanoma-associated antigens].
    Kageshita T; Ishihara K
    Gan To Kagaku Ryoho; 1985 Sep; 12(9):1744-8. PubMed ID: 3899015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The NK function elucidated with respect to effector cells, target cells and other immunological in vitro tests.
    Kristensen E
    Tokai J Exp Clin Med; 1983 Dec; 8(5-6):449-53. PubMed ID: 6681340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunology and immunotherapy of human malignant melanoma.
    Bystryn JC
    Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
    Mittelman A; Chen ZJ; Liu CC; Hirai S; Ferrone S
    Cancer Res; 1994 Jan; 54(2):415-21. PubMed ID: 8275478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of surface antigens of transplantable melanomas in hamster on the basis of the macrophage migration inhibition test.
    Kozłowska K; Zurawska-Czupa B; Kostulak A
    Arch Immunol Ther Exp (Warsz); 1981; 29(1):137-42. PubMed ID: 7283676
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human malignant melanoma cells: morphological and immunological variations.
    Hakim AA
    Neoplasma; 1977; 24(1):81-99. PubMed ID: 840339
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Cutaneous, cellular immunity in malignant melanoma].
    Kehrer HC
    Wien Klin Wochenschr; 1991; 103(13):396-7. PubMed ID: 1897233
    [No Abstract]   [Full Text] [Related]  

  • 53. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    Rosenberg SA; White DE
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status.
    Mavligit G; Gutterman JU; McBride C; Hersh EM
    Prog Exp Tumor Res; 1974; 19():222-52. PubMed ID: 4612607
    [No Abstract]   [Full Text] [Related]  

  • 55. Studies of humoral and cell-mediated immunity in human melanoma.
    Mukherji B; Nathanson L; Clark DA
    Yale J Biol Med; 1973 Dec; 46(5):681-92. PubMed ID: 4130586
    [No Abstract]   [Full Text] [Related]  

  • 56. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
    Kokoschka EM; Cerni C; Micksche M
    Oncology; 1977; 34(5):229-33. PubMed ID: 917456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Cellular immunity in melanomalignome (author's transl)].
    Fritz J; Grond K; Tilz GP
    Arch Dermatol Res (1975); 1976 Apr; 255(2):203-9. PubMed ID: 1275554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. IgA as a blocking factor in human malignant melanoma.
    O'Neill PA; Romsdahl MM
    Immunol Commun; 1974; 3(5):427-38. PubMed ID: 4214759
    [No Abstract]   [Full Text] [Related]  

  • 59. Immunotherapy in patients with melanoma.
    Seiger HF; Shingleton WW; Metzgar RS; Buckley CE
    Ann Surg; 1973 Sep; 178(3):352-9. PubMed ID: 4269702
    [No Abstract]   [Full Text] [Related]  

  • 60. Potentiation and arming of lymphocyte mediated immunity by sera from melanoma patients.
    Vanwijck R; Bouillenne C; Malek-Mansour S
    Eur J Cancer (1965); 1975 Apr; 11(4):267-76. PubMed ID: 1079770
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.